ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 148 filers reported holding ACCELERON PHARMA INC in Q4 2016. The put-call ratio across all filers is 3.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $7,056,000 | +3.3% | 276,525 | +46.5% | 0.00% | 0.0% |
| Q3 2016 | $6,830,000 | +5.2% | 188,731 | -1.2% | 0.00% | 0.0% |
| Q2 2016 | $6,492,000 | +28.7% | 191,044 | -0.1% | 0.00% | 0.0% |
| Q1 2016 | $5,045,000 | -11.5% | 191,173 | +63.6% | 0.00% | 0.0% |
| Q4 2015 | $5,699,000 | +97.2% | 116,888 | +0.7% | 0.00% | +50.0% |
| Q3 2015 | $2,890,000 | -17.2% | 116,042 | +5.2% | 0.00% | 0.0% |
| Q2 2015 | $3,491,000 | -8.3% | 110,328 | +10.3% | 0.00% | 0.0% |
| Q1 2015 | $3,808,000 | +9.5% | 100,053 | +12.0% | 0.00% | 0.0% |
| Q4 2014 | $3,479,000 | +110.6% | 89,301 | +63.5% | 0.00% | +100.0% |
| Q3 2014 | $1,652,000 | -10.1% | 54,626 | +1.0% | 0.00% | 0.0% |
| Q2 2014 | $1,838,000 | -3.0% | 54,100 | -1.5% | 0.00% | 0.0% |
| Q1 2014 | $1,895,000 | +13.7% | 54,907 | +30.4% | 0.00% | 0.0% |
| Q4 2013 | $1,667,000 | – | 42,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |